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Abstract EMR2 is a human myeloid-restricted member of the
EGF-TM7 receptor family that contains a highly conserved
G protein-coupled receptor proteolysis site (GPS) in the mem-
brane-proximal region. Here the post-translational proteolytic
cleavage of EMR2 at GPS was investigated. We show the
cleavage occurs at Leu517-Ser518 and is independent of the trans-
membrane domains. The non-covalent association of the result-
ing extracellular K-subunit and transmembrane L-subunit re-
quires a minimum of eight amino acids in the L-subunit. The
GPS motif is necessary, but not su⁄cient for receptor cleavage,
which requires the entire extracellular stalk. Thus, an alterna-
tively spliced EMR2 isoform with a truncated stalk fails to
undergo proteolytic cleavage. Alternative splicing therefore pro-
vides a means to regulate GPS cleavage, producing receptors
with two distinct structures.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, a novel group of seven-transmembrane
(7TM) receptors, termed long N-terminal family B G pro-
tein-coupled receptor (GPCR)-related 7TM (LNB-TM7) re-
ceptors, containing a class B GPCR-related 7TM moiety
and a large N-terminal extracellular domain (ECD), has at-
tracted much attention due to several unique features [1^3]. In
addition to the 7TM domain that may transduce cellular sig-
nals, the ECD of these molecules contains multiple repeats of
protein modules that are thought to be involved in protein^
protein interactions. Furthermore, the expression of LNB-
TM7 molecules is restricted to speci¢c cell types or tissues
such as leukocytes, smooth muscle cells, epididymal epithelial
cells or brain [1]. Thus, these unique receptors are believed to
play important roles in cell type/tissue-speci¢c functions
through cellular adhesion via the ECD, followed by signal
transduction through the 7TM domain.
Another common characteristic of the LNB-TM7 molecules
is a highly conserved Cys-rich domain in the membrane-prox-
imal region [1]. A post-translational proteolytic cleavage event
within the Cys-box has been linked to the generation of het-
erodimeric receptors composed of an extracellular K-subunit
and a 7TM L-subunit [4]. Hence, the Cys-box has also been
named the GPCR proteolysis site (GPS) [4,5]. However, a
search in the protein databases has yielded several other pro-
teins outside the LNB-TM7 family that also contain the con-
served GPS motif [6]. These include PKD-1, the human poly-
cystic kidney disease protein 1 [7,8], suREJ3, a channel-like
11-span transmembrane protein [9] and hPKDREJ, the hu-
man homologue of suREJ3 [10], suggesting that the GPS mo-
tif and its associated proteolytic cleavage activity are widely
used by cell surface receptors. Although the functional signi¢-
cance of the GPS motif-associated proteolysis remains elusive,
the presence of the highly conserved GPS motif in such a
diverse array of receptors is suggestive of a common role in
receptor function or regulation.
The epidermal growth factor-like domain containing TM7
(EGF-TM7) receptors [11,12] belong to a subgroup of the
LNB-TM7 family and consist of tandem repeats of N-termi-
nal EGF-like domains and a stalk region at the extracellular
region. The EGF-like domains of the EGF-TM7 receptors
have been shown to mediate cell^cell interaction by binding
to speci¢c cellular proteins [13^17]. The stalk region contains
a high percentage of Ser and Thr residues that are potential
O-glycosylation sites [11,12]. In addition, multiple potential
N-glycosylation sites have also been identi¢ed in the stalk.
Thus, the stalk region of the EGF-TM7 receptors is thought
to be highly glycosylated and act as a mucin-like domain with
a rigid structure. EMR2 is a member of the EGF-TM7 family
restricted to human myeloid cells including monocytes, mac-
rophages and granulocytes [18,19]. A cellular ligand speci¢c to
the EGF-like domains of the largest EMR2 isoform has been
identi¢ed recently (Stacey et al., Blood, in press). Within the
EGF-TM7 family, EMR2 is most related to CD97 in the
EGF-like domains (97.5% identity) and to EMR3 in the
TM7 domain (85% identity). All EGF-TM7 receptors except
EMR1 contain a consensus GPS motif at the most C-terminal
end of the stalk region very close to the TM domain. In recent
years, proteolytic cleavage of several EGF-TM7 receptors in-
cluding CD97, ETL and EMR4 has been demonstrated
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[16,20,21]. Using a newly developed EMR2 stalk-speci¢c
monoclonal antibody (mAb), we have recently shown that
EMR2 is also proteolytically cleaved [19]. To understand
this novel post-translational modi¢cation further, we herein
report the role of the extracellular stalk and the GPS motif
in EMR2 processing.
2. Materials and methods
2.1. Materials
All chemicals and reagents were obtained from Sigma unless other-
wise speci¢ed. Cell culture media and supplements were purchased
from Invitrogen (Carlsbad, CA, USA). EMR2-speci¢c 2A1 mAb
(mouse IgG1 subtype) was a⁄nity-puri¢ed from hybridoma superna-
tant as previously described [19].
2.2. Construction of expression vectors
All expression vectors were constructed on pcDNA3.1(+) (Invitro-
gen) unless otherwise speci¢ed. For the construction of vectors encod-
ing truncated EMR2(1, 2, 5) proteins, EMR2-TM1 and sEMR2, gene-
speci¢c primers were used to amplify the desired cDNA fragments
and subcloned into pcDNA3.1(+). For the construction of vectors
encoding various EMR2-mouse fragment crystallisable (mFc) fusion
proteins, a previously described expression construct containing a
mFc DNA fragment and a biotinylation signal was used [16]. A panel
of gene-speci¢c primers was used to generate DNA fragments encod-
ing various truncated EMR2 stalk regions, which were subsequently
subcloned to generate the following EMR2-mFc constructs:
EMR2(529)mFc, EMR2(526)mFc, EMR2(522)mFc, EMR2(518)mFc,
EMR2(310)mFc, EMR2v(260^487)mFc, EMR2v(260^479)mFc,
EMR2v(478^487)mFc, EMR2v(260^449)mFc, EMR2v(260^420)-
mFc, EMR2v(260^380)mFc, EMR2v(260^340)mFc and EMR2v-
(260^290)mFc. EMR2(534)mFc represents the fusion protein with a
full-length extracellular domain. A mFc expression construct, pSec-
mFc, encoding only the mFc protein was generated for use as a
positive control by subcloning the mFc fragment into the pSecTag2-A
vector (Invitrogen). The site-directed EMR2-mFc mutants, EMR2(1,
2, 5)-S518A-mFc and EMR2(1, 2, 5)-S519A-mFc were made accord-
ing to the protocols suggested by the manufacturer (GeneEditor Mu-
tagenesis System, Promega).
2.3. Cell culture
All culture media were supplemented with 10% heat-inactivated
foetal calf serum, 2 mM L-glutamine, 50 IU/ml penicillin and 50 Wg/
ml streptomycin. All cells were incubated at 37‡C in a 5% CO2, 95%
humidity incubator. Human embryonic kidney (HEK) 293T cells were
grown in Dulbecco’s modi¢ed Eagle’s medium and CHO-K1 cells in
Ham’s F-12 medium. EMR2 expression constructs were transfected
into cells cultured in 100 mm dishes using Lipofectamine1 (Life Tech-
nologies) as previously described [18]. 16^18 h post transfection, cells
were washed and fed with fresh Opti-MEM I for a further 2^3 days
before collecting protein samples.
2.4. Puri¢cation of soluble EMR2-mFc fusion proteins
HEK293T cells were transfected with 40 Wg DNA per 175 cm2 £ask
using calcium phosphate precipitation as previously described [22].
The medium was replaced with 25 ml serum-free Opti-MEM I 16^
18 h post transfection and incubated for a further 72 h. Conditioned
medium was collected, spun and passed through a 0.45 Wm ¢lter,
followed by protein A-Sepharose 4 Fast Flow (Amersham Pharmacia
Biotech) column puri¢cation as previously described [16].
2.5. Protein analysis
Conditioned media from transfected cells were spun at 2000 rpm at
4‡C for 20 min followed by 100 000 rpm at 4‡C for 20 min. The
supernatant was collected and stored at 380‡C until use. Total cell
lysates were collected in cell lysis bu¡er (20 mM Tris^HCl, pH 7.4,
5 mM MgCl2, 100 mM NaCl, 1 mM sodium orthovanadate, 1 mM
aminoethyl benzenesulfonyl £uoride, 5 mM levamisole, 1UCom-
plete1 (Roche) protease inhibitors). Similar amounts of EMR2 pro-
tein samples were subjected to standard sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and Western blot
analysis as described previously [16] using 8% gels and 2A1 mAb or
an anti-mouse Fc-speci¢c mAb (Sigma) followed by appropriate sec-
ondary antibodies for enhanced chemiluminescence detection (Amer-
sham). For N-terminal amino acid sequencing, 10 Wg of the puri¢ed
EMR2-mFc fusion protein was separated on a 10% Novex Bis-Tris
NuPAGE precast gel (Invitrogen) at 200 mA per gel in a Novex XCell
II Mini-cell gel apparatus. The gel was electroblotted to a Novex 0.2
Wm polyvinylidene di£uoride membrane (Invitrogen) and stained with
Coomassie brilliant blue. The desired V37 kDa band was excised,
washed extensively with 10% methanol and subjected to sequencing
on an Applied Biosystems 494A ‘Procise’ protein sequencer (Perkin
Elmer, Applied Biosystems Division, Warrington, UK) using standard
sequencing cycles. The £uorescence-activated cell sorting (FACS)
analysis of the cell surface EMR2 expression was done as previously
described [18].
3. Results and discussion
3.1. EMR2 is a heterodimeric cell surface receptor derived from
a 7TM-independent proteolytic cleavage event
To examine the proteolytic cleavage of EMR2 further, ex-
pression constructs encoding the full-length as well as trun-
cated EMR2 proteins were generated (Fig. 1A). Western blot
analysis showed that a broad band of V45^75 kDa was ob-
served in total cell lysates but not in conditioned media of
EMR2-TM7- or EMR2-TM1-transfected cells (Fig. 1B). In
cells transfected with sEMR2, a protein band of 60^75 kDa
was observed in conditioned media while a V40^60 kDa
band was detected in total cell lysates, believed to be the
immature protein precursor of the mature soluble protein.
The broad bands are due to protein glycosylation as predicted
from the amino acid sequences. This was subsequently con-
¢rmed by de-glycosylation experiments (Chang et al., unpub-
lished data). No visible bands were identi¢ed in samples from
mock-transfected cells (Fig. 1B). Detection of similar-sized
EMR2 proteins from cells transfected with EMR2 proteins
of di¡erent expected lengths (sEMR2, EMR2-TM1 and
EMR2-TM7) suggested that EMR2 is indeed proteolytically
cleaved and that the TM region is not required for cleavage.
Furthermore, the detection of EMR2 in total cell lysates but
not in conditioned media indicated that the cleaved extracel-
lular subunit remains associated with the TM subunit on the
cell surface.
To con¢rm these ¢ndings, an EMR2-mFc fusion protein
composed of the entire EMR2 extracellular region and an
mFc fragment was generated. Analysis of supernatants from
cells transfected with either control mFc or EMR2-mFc pro-
duced protein bands of similar sizes when probed with anti-
mFc mAb, while no signal was observed in samples contain-
ing sEMR2 proteins (Fig. 1C). On the other hand, when
probed with 2A1 mAb, EMR2-mFc was shown to produce
a protein species the same size as that of sEMR2 protein (Fig.
1D). These results indicate that the EMR2 fusion protein is
cleaved in close proximity to the mFc fragment at the C-ter-
minus of the stalk, similar to the cleavage of the membrane
form of EMR2 proteins. Furthermore, as the fusion protein
did not possess any TM moiety, the cleavage event is clearly
TM-independent. Finally, the association of the cleaved extra-
cellular subunit with the TM subunit on the cell surface was
con¢rmed by cell surface immunostaining of cells transfected
with either EMR2-TM7 or EMR2-TM1 (data not shown and
Fig. 3). It is therefore evident that the post-translational mod-
i¢cation of EMR2 protein involves TM-independent proteo-
lytic cleavage and non-covalent association of two cleaved
subunits on cell surface.
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3.2. Mapping of the EMR2 cleavage site
To locate the exact cleavage site, EMR2(534)mFc fusion
protein was puri¢ed and resolved on a 10% polyacrylamide
gel. Two products representing the extracellular domain
(V60^70 kDa) and the mFc fragment (V37 kDa) were visi-
ble (Fig. 1E). N-terminal amino acid sequencing of the mFc-
containing fragment produced 10 residues, SSFAVLMAHY,
which are identical to residues 518^527 of EMR2 (Fig. 1E).
Fig. 1. EMR2 is a heterodimeric cell surface receptor. A: Schematic representation of the genetically engineered EMR2 proteins. The EGF-like
motif is represented by a triangle, the stalk region by a black line and the TM region by a zig-zag line. The mFc fragment is shown as a dimer
of two circles. The number denotes the individual EGF-like domain. B: Western blot analysis showing the detection of EMR2 protein by 2A1
mAb in conditioned media (lanes 1, 3, 5, 7) and total cell lysates (lanes 2, 4, 6, 8) of HEK293T cells transfected with sEMR2 (lanes 3, 4),
EMR2-TM1 (lanes 5, 6), or EMR2-TM7 construct (lanes 7, 8). Samples from mock-transfected cells (lanes 1, 2) were used as a negative con-
trol. C,D: Western blot analysis of conditioned media from HEK293T cells transfected with mFc (lane 1), EMR2-mFc (lane 2), or sEMR2
(lane 3) under reducing (R) and non-reducing (NR) conditions using either anti-mFc (C) or 2A1 mAb (D). E: Coomassie brilliant blue staining
of the puri¢ed EMR2-mFc protein (lane 2) reveals two protein fragments of V37 kDa and V60^70 kDa. The V37 kDa fragment was excised
for N-terminal sequencing, which produced 10 amino acid residues (underlined) that are identical to residues 518^527 of the EMR2 protein.
Lane 1 contains molecular weight standard. F: Western blot analysis of conditioned media from HEK293T cells transfected with site-directed
mutants, EMR2-S518A-mFc (lane 1) and EMR2-S519A-mFc (lane 2), using anti-mFc or 2A1 mAb. G: Western blot analysis of cell lysate
from HEK293T cells transfected with the wild-type EMR2-TM7 (lane 1), site-directed mutants, EMR2-S518A-TM7 (lane 2) and EMR2-S519A-
TM7 (lane 3), using 2A1 mAb. H: Amino acid sequence alignment of the GPS motif of LNB-TM7 proteins. The four conserved Cys residues
are boxed with black background whereas the other conserved residues are boxed with grey background. The consensus proteolytic cleavage
site is indicated by arrow. The letter before each protein denotes the species from which the protein is derived: h, human; m, mouse; r, rat.
The number in parentheses indicates the sequence homology of the aligned GPS domain in comparison to that of EMR2.
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The cleavage therefore appeared to take place at the peptide
bond between Leu517 and Ser518. This is consistent with the
cleavage sites identi¢ed previously for CL1 [4], ETL [21], Ig-
hepta [23] and mEMR4 [16] (Fig. 1H). To con¢rm this, site-
directed mutant EMR2-mFc fusion proteins containing a
Ser518Ala mutation or a Ser519Ala mutation were generated.
Western blot analysis showed that the EMR2-S518A-mFc
protein, but not the EMR2-S519A-mFc protein, failed to
undergo cleavage and was manifested as an intact single chain
protein (Fig. 1F). The same result was obtained when the
membrane form of the molecules (EMR2-TM7, EMR2-
S518A-TM7 and EMR2-S519A-TM7) was examined (Fig.
1G).
3.3. The role of the GPS motif and extracellular stalk in the
proteolytic cleavage of EMR2
Although the consensus GPS cleavage site is established
here and elsewhere [4,16,21], little is known about the involve-
ment of the GPS motif and stalk in the cleavage process.
Recently, a functional role for the GPS domain in receptor
cleavage has been shown in CL-1, where mutations in the
GPS domain render the molecule resistant to intracellular
cleavage [24]. Likewise, germline point mutations at the extra-
cellular REJ domain prevent PKD-1 cleavage, leading to poly-
cystic kidney diseases [25]. To evaluate the role of the GPS
motif and the stalk in EMR2 cleavage, various EMR2-mFc
constructs with truncated stalk regions were employed (Fig.
2A). Western blot analysis showed that the proteolytic cleav-
age occurred in EMR2(526)mFc, EMR2(529)mFc and the
EMR2(534)mFc protein that contains the full-length ECD
(Fig. 2B). However, EMR2(518)mFc and EMR2(522)mFc
proteins were not proteolytically processed indicating that in
the context of an intact stalk, a minimum of eight additional
amino acid residues C-terminal to the cleavage site is required
for cleavage (Fig. 2B). Interestingly, these eight amino acid
residues are highly conserved among all known GPS motifs
(Fig. 1H).
Next, the requirement of the GPS motif was demonstrated
using EMR2v(260^479)mFc, EMR2v(260^487)mFc and
EMR2v(478^487)mFc fusion proteins, containing a complete
GPS motif, a partial GPS motif, and a stalk with a minimally
deleted GPS motif, respectively (Fig. 2A,C). All three proteins
failed to undergo proteolytic cleavage, indicating that the GPS
motif is necessary, but not su⁄cient for the cleavage process.
It also suggested that the rest of the stalk might be involved.
The requirement of the stalk was con¢rmed by a series of
EGF Mucin-like stalk GPS mFc
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Fig. 2. The GPS motif and the stalk are essential for the proteolytic cleavage of EMR2. A: Schematic representation of the truncated EMR2
proteins used for the GPS cleavage study. The sequence of the GPS motif is shown with residues highlighted in grey corresponding to the posi-
tions of the truncation. The conserved residues are underlined. The cleavage site is indicated by arrow. B: Western blot analysis of conditioned
media from cells transfected with empty vector (lane 1), mFc (lane 2), EMR2(518)mFc (lane 3), EMR2(522)mFc (lane 4), EMR2(526)mFc
(lane 5), EMR2(529)mFc (lane 6) or EMR2(534)mFc (lane 7). Blots were probed with anti-mFc (left panel) or 2A1 mAb (right panel). C:
Western blot analysis of conditioned media from cells transfected with EMR2v(260^487)mFc (lane 1), EMR2v(260^479)mFc (lane 2),
EMR2v(478^487)mFc (lane 3), EMR2v(260^449)mFc (lane 4), EMR2v(260^420)mFc (lane 5), EMR2v(260^380)mFc (lane 6), EMR2v(260^
340)mFc (lane 7) or EMR2(310)mFc (lane 8). Blots were probed with anti-mFc (left panel) or 2A1 mAb (right panel).
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stalk-truncated mutants, EMR2v(260^449)mFc, EMR2v-
(260^420)mFc, EMR2v(260^380)mFc, EMR2v(260^340)mFc
and EMR2v(260^290)mFc, all of which were produced as a
unprocessed single polypeptide chain (Fig. 2C). Together
these results indicate that in addition to the GPS motif, the
entire stalk is also required for the cleavage process. Further-
more, based upon the reactivity of 2A1 to the stalk-truncated
mutants, the epitope of the EMR2 stalk-speci¢c 2A1 mAb is
likely to be located between residues 310 and 340 (Fig. 2).
However, a discontinuous epitope sequence cannot be com-
pletely ruled out at present.
To shed more light on the importance of an intact stalk for
receptor proteolysis, the cleavage of a EMR2-mFc fusion pro-
tein containing a naturally truncated stalk was evaluated (Fig.
3). Due to the di¡erential usage of splicing acceptors at exon
12, this alternatively spliced stalk lacked 11 amino acid resi-
dues (amino acids 396^414) in comparison to the full-length
stalk (Fig. 3A) [18]. As shown in Fig. 3B, EMR2-mFc fusion
protein containing this alternatively spliced stalk was not
cleaved, strengthening the notion that a full-length intact stalk
is essential for the proteolytic processing of EMR2. Again, the
membrane form of this EMR2 isoform is also not cleaved
(data not shown). This result shows that alternative splicing
in the stalk region can regulate the receptor cleavage at the
GTGACCCAGGCCCTTCTGTGGTGGGCCTTGTCTCCATTCCAGGGATGGGCAAGTTGCTG
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Fig. 3. An alternatively spliced EMR2 isoform containing a truncated stalk was not cleaved. A: Nucleotide and amino acid sequences showing
the alternative splicing at exon 12 of EMR2. The 33 nucleotides and the corresponding 11 amino acid residues that are spliced out are under-
lined and boxed with grey background, respectively. The boundary between exons 11 and 12 is also shown. B: Western blot analysis of condi-
tioned media from cells transfected with EMR2-mFc constructs containing the alternatively spliced stalk (lane 1) or the full-length stalk (lane
2). C,D: Association of EMR2-K and -L subunits in vitro (C) and in vivo (D). C: EMR2(526)mFc (lane 1), EMR2(529)mFc (lane 2), and
EMR2(534)mFc (lane 3) proteins were immunoprecipitated by protein A Dynabeads, washed, and subjected to SDS^PAGE and Western blot-
ting using 2A1 mAb (right panel) or anti-mFc mAb (left panel). D: FACS analysis of cell surface EMR2 expression on EMR2(526)-TM7-,
EMR2(529)-TM7- and EMR2(534)-TM7-transfected CHO-K1 cells using 2A1 mAb (dark solid line). An isotype-match (mouse IgG1) antibody
(grey area) was used as a negative control. Cells transfected with pcDNA3.1 were used as a negative control for transfection.
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GPS motif and produce either a heterodimeric or a single-
chain receptor. The functional di¡erence between the two re-
ceptor isoforms remains to be determined.
3.4. The sequence requirement for the association of EMR2
heterodimeric subunits
Using the stalk-truncated EMR2-mFc fusion proteins de-
scribed above, the sequence requirement for subunit associa-
tion was investigated. The K-subunits of EMR2(526)mFc,
EMR2(529)mFc and EMR2(534)mFc are readily detected
from protein A-immunoprecipitated samples, due to the asso-
ciation of the K-subunit with the mFc fragment (Fig. 3C).
Likewise, the K-subunits of the EMR2(526)-TM7, EMR2-
(529)-TM7 and EMR2(534)-TM7 proteins were detected on
the cell surface (Fig. 3D), but not in the conditioned media
(data not shown). This indicates that as few as eight amino
acid residues in the L-subunit are su⁄cient for the cleavage, as
well as the non-covalent association of K- and L-receptor sub-
units.
The GPS motif was originally named due to its involvement
in the proteolytic cleavage of latrophilin/CL-1 [4,5] and has
since been identi¢ed in a wide variety of cell surface proteins
including members of the LNB-TM7 family as well as PKD-1,
suREJ3, and hPKDREJ [9,10,26]. The presence of the highly
conserved GPS motif in such a diverse array of cell surface
proteins suggests that the GPS motif-associated proteolysis is
evolutionarily conserved and might be important for the func-
tion or regulation of these receptors. Consistent with this no-
tion, Krasnoperov et al. have shown that mutations in the
GPS domain make CL-1 resistant to the cleavage and impair
its tra⁄cking to the cell surface [24]. Moreover, cleavage of
PKD-1 at the conserved GPS site has recently been demon-
strated and germline point mutations at the extracellular REJ
domain adjacent to the GPS motif prevent PKD-1 cleavage,
leading to polycystic kidney disease [25]. Since PKD-1 is an
11-span TM protein, the GPS cleavage process is apparently
not restricted to a particular TM conformation. Therefore, the
TM conformation-independent cleavage and the requirement
of an intact extracellular stalk for GPS cleavage seem to rep-
resent common characteristics of this unique post-translation-
al protein modi¢cation (Figs. 1 and 2). It is possible that the
speci¢c recognition of the intact stalk, probably through cor-
rect folding, provides a structural determinant for receptor
cleavage. Finally, the requirement of only eight conserved
amino acid residues in the L-subunit for receptor cleavage
and subunit association is also intriguing (Fig. 3). It is noted
that the majority of these residues are small and hydrophobic,
a feature that might be relevant to their dual roles in the
cleavage of the GPS motif and the association of the cleaved
subunits (Figs. 2 and 3). Since the putative protease respon-
sible for GPS cleavage remains unknown, it is hoped that the
information obtained from the present study on sequence re-
quirement and substrate speci¢city will facilitate the identi¢-
cation of the protease involved and further contribute to the
understanding of receptor proteolysis at the GPS motif.
Acknowledgements: We would like to thank Mr Antony Willis for
performing N-terminal amino acid sequencing and Dr D.H. Wresch-
ner for his insightful discussion. Dr J. Davies is thanked for critical
reading of the manuscript. This study is supported by grants from
British Heart Foundation (PG/02/144 to H.-H.L.) and Wellcome
Trust (G.-W.C. and M.S.). H.-H.L. has been supported in part by a
research grant from Celltech RpD. S.G.’s research is supported by
grants from the Medical Research Council, UK. J.H. is a fellow of the
Royal Netherlands Academy of Arts and Sciences.
References
[1] Stacey, M., Lin, H.H., Gordon, S. and McKnight, A.J. (2000)
Trends Biochem. Sci. 25, 284^289.
[2] Hay£ick, J.S. (2000) J. Receptor Signal Transduct. Res. 20, 119^
131.
[3] Harmar, A.J. (2001) Genome Biol. 2, 1^10.
[4] Krasnoperov, V.G. et al. (1997) Neuron 18, 925^937.
[5] Krasnoperov, V., Bittner, M.A., Holz, R.W., Chepurny, O. and
Petrenko, A.G. (1999) J. Biol. Chem. 274, 3590^3596.
[6] Ponting, C.P., Hofmann, K. and Bork, P. (1999) Curr. Biol. 9,
R585^8.
[7] The European Polycystic Kidney Disease Consortium (1994) Cell
77, 881^94.
[8] The International Polycystic Kidney Disease Consortium (1995)
Cell 81, 289^98.
[9] Mengerink, K.J., Moy, G.W. and Vacquier, V.D. (2002) J. Biol.
Chem. 277, 943^948.
[10] Hughes, J., Ward, C.J., Aspinwall, R., Butler, R. and Harris,
P.C. (1999) Hum. Mol. Genet. 8, 543^549.
[11] McKnight, A.J. and Gordon, S. (1996) Immunol. Today 17, 283^
287.
[12] McKnight, A.J. and Gordon, S. (1998) J. Leukoc. Biol. 63, 271^
280.
[13] Hamann, J., Vogel, B., van Schijndel, G.M. and van Lier, R.A.
(1996) J. Exp. Med. 184, 1185^1189.
[14] Qian, Y.M., Haino, M., Kelly, K. and Song, W. (1999) Immu-
nology 98, 303^311.
[15] Stacey, M., Lin, H.H., Hilyard, K.L., Gordon, S. and McKnight,
A.J. (2001) J. Biol. Chem. 276, 18863^18870.
[16] Stacey, M., Chang, G.W., Sanos, S.L., Chittenden, L.R., Stubbs,
L., Gordon, S. and Lin, H.H. (2002) J. Biol. Chem. 277, 29283^
29293.
[17] Hamann, J., van Zeventer, C., Bijl, A., Molenaar, C., Tesselaar,
K. and van Lier, R.A. (2000) Int. Immunol. 12, 439^448.
[18] Lin, H.H., Stacey, M., Hamann, J., Gordon, S. and McKnight,
A.J. (2000) Genomics 67, 188^200.
[19] Kwakkenbos, M.J., Chang, G.W., Lin, H.H., Pouwels, W., de
Jong, E.C., van Lier, R.A., Gordon, S. and Hamann, J. (2002)
J. Leukoc. Biol. 71, 854^862.
[20] Gray, J.X. et al. (1996) J. Immunol. 157, 5438^5447.
[21] Nechiporuk, T., Urness, L.D. and Keating, M.T. (2001) J. Biol.
Chem. 276, 4150^4157.
[22] Lin, H.H. et al. (2001) J. Biol. Chem. 276, 24160^24169.
[23] Abe, J., Fukuzawa, T. and Hirose, S. (2002) J. Biol. Chem. 277,
23391^23398.
[24] Krasnoperov, V., Lu, Y., Buryanovsky, L., Neubert, T.A.,
Ichtchenko, K. and Petrenko, A.G. (2002) J. Biol. Chem. 277,
46518^46526.
[25] Qian, F. et al. (2002) Proc. Natl. Acad. Sci. USA 99, 16981^
16986.
[26] Moy, G.W., Mendoza, L.M., Schulz, J.R., Swanson, W.J.,
Glabe, C.G. and Vacquier, V.D. (1996) J. Cell Biol. 133, 809^
817.
FEBS 27438 3-7-03
G.-W. Chang et al./FEBS Letters 547 (2003) 145^150150
